Ratings by Citi (Eric Joseph)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 10/14/2026 | Alnylam Pharmaceuticals | ALNY | Maintain | Buy (N/A) |
|
Details | ||
| 9/23/2026 | Madrigal Pharmaceuticals | MDGL | New Coverage | Buy (N/A) |
518.83 (449.74) |
-13.32% | Details | |
| 9/8/2026 | Arrowhead Pharma | ARWR | New Coverage | Buy (N/A) |
86.49 (55.90) |
-35.37% | Details | |
| 8/13/2026 | Ascendis Pharma | ASND | Maintain | Buy (N/A) |
|
Details | ||
| 8/11/2026 | BridgeBio Pharma | BBIO | Maintain | Neutral (N/A) |
|
Details | ||
| 7/16/2026 | BridgeBio Pharma | BBIO | Maintain | Neutral (N/A) |
|
Details | ||
| 7/16/2026 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Buy (N/A) |
|
Details | ||
| 7/9/2026 | Ionis Pharmaceuticals | IONS | Maintain | Buy (N/A) |
|
Details | ||
| 6/9/2026 | PTC Therapeutics | PTCT | Upgrade | Buy (Neutral) |
70.87 (59.24) |
-16.41% | Details | |
| 5/18/2026 | Cytokinetics | CYTK | New Coverage | Buy (N/A) |
75.85 (61.95) |
-18.33% | Details | |
| 5/18/2026 | Ionis Pharmaceuticals | IONS | New Coverage | Buy (N/A) |
74.23 (42.94) |
-42.15% | Details | |
| 5/18/2026 | BridgeBio Pharma | BBIO | New Coverage | Neutral (N/A) |
66.13 (66.39) |
0.39% | Details | |
| 5/18/2026 | BioMarin Pharmaceutical Inc. | BMRN | New Coverage | Buy (N/A) |
51.81 (54.68) |
5.54% | Details | |
| 5/18/2026 | Ascendis Pharma | ASND | New Coverage | Buy (N/A) |
240.50 (225.25) |
-6.34% | Details | |
| 5/18/2026 | Alnylam Pharmaceuticals | ALNY | New Coverage | Buy (N/A) |
286.98 (231.83) |
-19.22% | Details |
